Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Randomised placebo-controlled trials of individualised homeopathic treatment: systematic review and meta-analysis

  • Robert T Mathie1Email author,
  • Suzanne M Lloyd2,
  • Lynn A Legg3,
  • Jürgen Clausen4,
  • Sian Moss5,
  • Jonathan RT Davidson6 and
  • Ian Ford2
Systematic Reviews20143:142

DOI: 10.1186/2046-4053-3-142

Received: 26 June 2014

Accepted: 12 November 2014

Published: 6 December 2014

Abstract

Background

A rigorous and focused systematic review and meta-analysis of randomised controlled trials (RCTs) of individualised homeopathic treatment has not previously been undertaken. We tested the hypothesis that the outcome of an individualised homeopathic treatment approach using homeopathic medicines is distinguishable from that of placebos.

Methods

The review’s methods, including literature search strategy, data extraction, assessment of risk of bias and statistical analysis, were strictly protocol-based. Judgment in seven assessment domains enabled a trial’s risk of bias to be designated as low, unclear or high. A trial was judged to comprise ‘reliable evidence’ if its risk of bias was low or was unclear in one specified domain. ‘Effect size’ was reported as odds ratio (OR), with arithmetic transformation for continuous data carried out as required; OR > 1 signified an effect favouring homeopathy.

Results

Thirty-two eligible RCTs studied 24 different medical conditions in total. Twelve trials were classed ‘uncertain risk of bias’, three of which displayed relatively minor uncertainty and were designated reliable evidence; 20 trials were classed ‘high risk of bias’. Twenty-two trials had extractable data and were subjected to meta-analysis; OR = 1.53 (95% confidence interval (CI) 1.22 to 1.91). For the three trials with reliable evidence, sensitivity analysis revealed OR = 1.98 (95% CI 1.16 to 3.38).

Conclusions

Medicines prescribed in individualised homeopathy may have small, specific treatment effects. Findings are consistent with sub-group data available in a previous ‘global’ systematic review. The low or unclear overall quality of the evidence prompts caution in interpreting the findings. New high-quality RCT research is necessary to enable more decisive interpretation.

Keywords

Individualised homeopathy Meta-analysis Randomised controlled trials Systematic review

Background

The nature of the research evidence in homeopathy is a matter of ongoing scientific debate. Homeopathy’s advocates tend to deny the worth of randomised controlled trials (RCTs) [1] or over-interpret their findings, whilst its critics dispute the therapy’s scientific rationale and the existence of any positive findings in the research literature [2]. There is a need to temper these divergent opinions by considering the existing RCT evidence from an objective, rigorous and transparent assessment of the research, reflecting its particular nature and intrinsic methodological quality.

Five systematic reviews have examined the RCT research literature on homeopathy as a whole, including the broad spectrum of medical conditions that have been researched and by all forms of homeopathy: four of these ‘global’ systematic reviews reached the conclusion that, with important caveats [3], the homeopathic intervention probably differs from placebo [47]. By contrast, the most recent global systematic review, by Shang et al., concluded there was “weak evidence for a specific effect of homeopathic remedies…compatible with the notion that the clinical effects of homeopathy are placebo effects” [8].

Four of the above reviews have distinguished RCTs of individualised homeopathy, either by mere identification [4, 8] or in formal sub-group analysis [6, 7]. In their overarching approaches, however, each of these five reviews has assessed together the RCT findings of all forms of homeopathy (individualised homeopathy, clinical homeopathy, complex homeopathy, isopathy) as if they are the same intervention. There are important differences between these therapeutic approaches, especially that individualised homeopathy typically involves a long interview between the practitioner and the patient, whereas the other three forms (non-individualised homeopathy) do not. For a placebo-controlled trial of individualised homeopathy, conclusions about ‘efficacy’ (specific effects) apply potentially to each or just some of the homeopathic medicines prescribed to the individual participants in that trial. A meta-analysis of such RCTs (including those with crossover design, which we excluded—see ‘Methods’) was published in 1998 [9], using methods that predated the current rigorous standards for conducting risk-of-bias assessments and sensitivity analysis: it reported a significant overall treatment effect that marginally was not sustained for the best-quality trials.

We aimed to clarify the results and inferences from RCTs of individualised homeopathy by conducting an up-to-date systematic review and meta-analysis to test the hypothesis: In the context of an RCT, and for the broad spectrum of medical conditions that have been researched, the main outcome of an individualised homeopathic treatment approach using homeopathic medicines is distinguishable from that of the same approach using placebos (i.e. individually prescribed homeopathic medicines have specific effects).

Methods

Methods comply with the PRISMA 2009 Checklist (see Additional file 1) and with our previously published protocol [10].

Search strategy, data sources and trial eligibility

A detailed description of the search methods used in this study has previously been published [11]. We conducted a systematic literature search to identify RCTs that compared individualised homeopathy with placebos, and for any medical condition. Each of the following electronic databases was searched from its inception up to the end of 2011, with a supplementary search of the same databases up to the end of 2013: AMED, CAM-Quest®, CINAHL, Cochrane Central Register of Controlled Trials, Embase, Hom-Inform, LILACS, PubMed, Science Citation Index and Scopus. For the 2012/13 update, CORE-Hom® was searched in addition, using the term ‘randomised’, ‘quasi-randomised’ or ‘unknown’ in the ‘Sequence generation’ field.

The full electronic search strategy for PubMed (Cochrane Highly Sensitive Search Strategy) is given in our previous paper [11]: ‘((homeopath* OR homoeopath*) AND ((randomized controlled trial [pt]) OR (controlled clinical trial [pt]) OR (randomized [tiab]) OR (placebo [tiab]) OR (clinical trials as topic [mesh:noexp]) OR (randomly [tiab]) OR (trial [ti]))) NOT (animals [mh] NOT humans [mh])’.

As stated in our published protocol [10], we then excluded trials of crossover design, of radionically prepared homeopathic medicines, of homeopathic prophylaxis, of homeopathy combined with other (complementary or conventional) intervention, or for other specified reasons. The final explicit exclusion criterion was that the trial’s team members—specifically the homeopathic practitioner/s—were not blinded to the assigned intervention. All remaining trials were eligible for systematic review.

Outcome definitions

We identified one ‘main outcome measure’ from each study using a refinement of the approaches adopted by Linde et al. and by Shang et al. [6, 8]. Our selection of each trial’s ‘main outcome measure’ at the study end-point (i.e. at the end of scheduled follow-up, unless otherwise indicated) was based on a pre-specified hierarchical list in order of greatest to least importance, recommended by the World Health Organization (WHO) [12]. The WHO approach is an internationally accepted method to ensure that a selected outcome is the most vital to the functioning and health of the patient: it thus ensured our consistent selection of the most important and objective outcome per trial.

Data extraction

Two reviewers (RTM and either JC, JRTD, LAL or SM) independently identified the ‘main outcome measure’ and extracted data for each trial using a standard recording approach [10]. Discrepancies in the identification and interpretation of data were discussed and resolved by consensus.

Assessment of risk of bias

We used the domains of assessment as per the Cochrane risk-of-bias appraisal tool [13]. The extracted information enabled appraisal of freedom from risk of bias: ‘Yes’ (low risk), ‘Unclear’ (uncertain risk) or ‘No’ (high risk). We applied this approach to each of seven domains: sequence generation (domain I), allocation concealment used to implement the random sequence (II), blinding of participants and study personnel (IIIa), blinding of outcome assessors (IIIb), incomplete outcome data (IV), selective outcome reporting (V), and other sources of bias (VI). The source of any research sponsorship (i.e. potential for vested interest) was taken into account for sub-group analysis (see below), but not in risk-of-bias assessment per se.

Reflecting appropriately the designated ‘main outcome measure’, we rated risk of bias for each trial across all seven domains and using the following classification [10]:

Rating A = Low risk of bias in all seven domains.

Rating Bx = Uncertain risk of bias in x domains; low risk of bias in all other domains.

Rating Cy.x = High risk of bias in y domains; uncertain risk of bias in x domains; low risk of bias in all other domains.

Designating an RCT as ‘reliable evidence’

An ‘A’-rated trial comprises reliable evidence. We designated a ‘B1’-rated trial reliable evidence if the uncertainty in its risk of bias was for one of domains IV, V or VI only (i.e. it was required to be judged free of bias for each of domains I, II, IIIa and IIIb).

Statistical analysis

Data

Mean, standard deviation and number of subjects were extracted for each continuous ‘main outcome’ and the standardised mean difference (SMD) calculated, reflecting whether a higher or a lower score was in the direction of the hypothesis favouring homeopathy; the number of favourable events and number of subjects were extracted for each dichotomous ‘main outcome’ and the odds ratio (OR) calculated. We did not adjust values to compensate for any inter-group differences at baseline.

For key meta-analyses, a single measure of ‘effect size’ was required to enable pooling of all relevant trials, and so SMD was transformed to OR using a recognised approximation method [10]. Random-effects meta-analysis models were used from the outset due to the known clinical heterogeneity among studies.

Study selection for meta-analysis

All RCTs that were included in the systematic review were potentially eligible for meta-analysis. If the original RCT paper did not provide or inform adequate information on our selected ‘main outcome’ to enable calculation of the SMD or the OR, we excluded the trial from meta-analysis and described the outcome as ‘not estimable’.

Heterogeneity and publication bias

The I 2 statistic was used to assess the variability between studies; this statistic can take values between 0% and 100%, with high values indicative of strong heterogeneity.

Funnel plots and Egger’s test were used to assess publication bias [14, 15].

Sensitivity and sub-group analysis

Sensitivity and sub-group analyses were carried out, consistent with our published protocol [10]. The sensitivity analysis examined the impact on the pooled OR of trials’ risk-of-bias ratings. Included in sub-group analyses, we aimed to examine whether a trial’s homeopathic medicines had potency ≥12C or <12C (12-time serial dilution of 1:100 starting solution), a concentration sometimes regarded as equivalent to the ‘Avogadro limit’ for molecular dose [16].

Results

Included studies

The PRISMA flowchart from the original comprehensive literature search has been published previously [11] and comprises 489 records. The corresponding flowchart for RCT records published in 2012/13 is given in Additional file 2, which features 44 new records. A composite PRISMA flowchart, in standardised format, is given in Additional file 3.

Our updated literature search identified a total of five new records that were potentially eligible for the current review of RCTs that compared individualised homeopathy with placebos (Additional file 4, an update of the flowchart in our published protocol [10]). All five were single-blinded and thus ineligible for systematic review.

In total, therefore, 31 records fulfilled the relevant inclusion criteria. Data were non-extractable from 10 of those (see Additional file 4), leaving 21 records potentially available for meta-analysis. One of the included records reported findings from two RCTs. Thus, the systematic review comprises 32 RCTs, with meta-analysis of 22 of those RCTs.

Demographic data

The 32 RCTs represented 24 different medical conditions across 12 categories (Table 1). Homeopathic potency was ≥12C in 12 trials and was not exclusively ≥12C for 20 trials (mix of >12C and <12C for 12 trials; unstated for 8 trials). Vested interest was absent in four trials, uncertain in 18 and present in 10.
Table 1

Demographic data for 32 randomised controlled trials (RCTs) of individualised homeopathy

#

First author

Year

Category

Condition

Participants’demographics

Study setting

Potency≥12C/24D

Funding source

Free of vested interesta

A01

Andrade

1991

Rheumatology

Rheumatoid arthritis

Patients with active RA and fulfilling at least three pre-defined criteria

Rheumatic disease outpatient clinic, Escola Paulista de Medicina, São Paulo, Brazil

Mixed

None stated

U

A05

Bell

2004

Rheumatology

Fibromyalgia

Fibromyalgia patients

Private clinic in the USA

Mixed

External (government)

Y

A06

Bonne

2003

Mental disorder

Anxiety

Adults aged 18–65 years, of either sex, suffering from anxiety as defined by standard psychometric criteria

Department of Psychiatry, Hadassah University Hospital, Jerusalem, Israel

Y

None stated

U

A07

Brien

2011

Rheumatology

Rheumatoid arthritis

Adults formally diagnosed with RA for at least 2 years, who had relatively stable disease but some disease activity on entry

Rheumatology outpatient departments at three hospitals, UK

U

National Institute of Health Research; Samueli Institute, USA; Southampton Complementary Medicine Research Trust; Rufford Maurice Laing Foundation; Dreluso Pharmazeutika GmBH; National Health Service Fund for Science

Y

A09

Cavalcanti

2003

Dermatology

Uraemic pruritus

Dialysis for more than 6 months, moderate to severe pruritus, absence of other causes for pruritus

Haemodialysis centres, Rio de Janeiro state, Brazil

Mixed

None stated

U

A10

Chapman

1999

Neurology

Brain injury

Patients with mild traumatic brain injury

University medical school in the USA

Y

External (government; foundation; hom pharm providing all meds)

N

A11

de Lange de Klerk

1994

Respiratory infection

URTI

Children aged 1.5–10 years, with at least three upper respiratory tract infections in the past year or with two such episodes plus otitis media with effusion at the time of entry examination

Paediatric outpatient department of university hospital, Amsterdam, Netherlands

Mixed

Dutch Ministry of Welfare, Cultural Affairs, and Public Health

Y

A13

Fisher

2006

Dermatology

Eczema

Adults aged 18–65 years, of either sex, with planned treatment for dermatitis at the RLHH

Royal London Homoeopathic Hospital (RLHH), London, UK

Mixed

None stated

U

A14

Frass

2005

Surgery and anaesthesiology

Sepsis

Patients with severe sepsis

Intensive Care Unit at a university hospital in Austria

Y

None stated

U

A16

Gaucher

1994

Tropical disease

Cholera

Patients with cholera, in a state of dehydration requiring parenteral treatment

University of San Marcos, Lima, Peru

U

None stated; several acknowledged, including employee of hom pharm company

U

A18

Jacobs

1993

Gastroenterology

Childhood diarrhoea

Children aged 0.5–5 years, with history of acute diarrhoea

Participants’ homes, Leon, Nicaragua

Y

Boiron Research Foundation, Norwood, Pennsylvania, USA,

U

A19

Jacobs

1994

Gastroenterology

Childhood diarrhoea

Children with a history of acute diarrhoea

Nicaragua

Y

External, including hom pharm that might have provided the remedies for the trial

U

A20

Jacobs

2001

Ear, nose and throat

Otitis media (acute)

Patients with acute otitis media

Children’s clinic in the USA

Y

External (hom pharm—all remedies—research grant)

N

A21

Jacobs

2000

Gastroenterology

Childhood diarrhoea

Children with a history of acute diarrhoea

Nepal

Y

External (hom research foundation)

U

A22

Jacobs

2005b

Obstetrics and gynaecology

Menopause post breast cancer

Women with history of carcinoma or stage I–III breast cancer who had completed all surgery, chemotherapy and radiation treatment and who averaged at least three hot flushes per day for previous month

Private medical clinic, Seattle, USA

U

External (charity); meds donated by hom pharm

N

A23

Jacobs

2005a

Mental disorder

ADHD

Children, aged 6–12 years, meeting DSM-IV criteria for ADHD

Private homeopathic clinic in Seattle, USA

U

External (government); meds donated by hom pharm

N

A24

Jansen

1992

Gastroenterology

Proctocolitis

Active proctocolitis (proven by endoscopy and histology)

Outpatient dept, Maria Hospital, Tilburg, Netherlands

Y

None stated

U

A25

Kainz

1996

Dermatology

Warts

Children aged 6–12 years, with common warts on the back of hands

Department of Dermatology, University of Graz, Austria

Mixed

Firma Spagyra, Groding, Austria: ‘kindly provided’ homeopathic medicines and placebos. Otherwise, none stated

N

A26

Katz

2005

Mental disorder

Depression

Adults, aged 18–80 years, of either sex, suffering from major depressive episode of moderate severity as defined by DSM-IV

Lower Clapton group practice, east London, UK

U

Homeopathic Research Committee; Blackie Foundation Trust. Verum and placebo homeopathic medicines donated by Laboratoires Boiron

N

A30

Naudé

2010

Mental disorder

Insomnia

Insomnia sufferers (identified through local advertising)

South Africa

Mixed

None stated

U

A31

Rastogi ( a)

1999

Immune disorder

HIV

Adults aged 18–50 years, of either sex, with positive antibody reaction to HIV-1 or HIV-2 or both confirmed by repeat ELISA and/or Western blot

Regional Research Institute for Homoeopathy, Mumbai, India

Mixed

None stated

U

A31

Rastogi ( b)

1999

Immune disorder

HIV

Adults aged 18–50 years, of either sex, with positive antibody reaction to HIV-1 or HIV-2 or both confirmed by repeat ELISA and/or Western blot

Regional Research Institute for Homoeopathy, Mumbai, India

Mixed

None stated

U

A32

Sajedi

2008

Neurology

Cerebral palsy

Children aged 1–5 years, with mild to moderate spasm due to cerebral palsy

Saba Clinic (Developmental Disorder Center), Tehran, Iran

U

Internal

U

A33

Siebenwirth

2009

Dermatology

Eczema

Adults aged 18–35 years with at least a 1-year history of atopic dermatitis (>20% of skin surface)

Klinik und poliklinik für Dermatologie und Allergologie am Biederstein, Munich, Germany

Mixed

The study medications gifted by Deutsche Homöopathie-Union (DHU). Funded by Karl und Veronica Carstens-Stiftung

N

A34

Steinsbekk

2005

Respiratory infection

URTI

Children, under 10 years old, who had been to a medical doctor for URTI

In children’s own homes, recruited mainly from those previously diagnosed with URTI when attending a hospital casualty department

Y

External: Norwegian Research Council. Homeoden Belgium made the medicines

U

A35

Straumsheim

2000

Neurology

Migraine

Adults aged 18–65 years, of either sex, diagnosed according to International Headache Society classification criteria

Arena Medisinske Senter, Oslo, Norway

Mixed

DCG Farmaceutia (Gotenborg): supplied all homeopathic medicines. Norwegian Research Council

N

A36

Thompson

2005

Obstetrics and gynaecology

Menopause post breast cancer

Women who attended oncology centre for breast cancer, did not have metastatic disease, were not on any other treatment and experiencing more than three hot flushes per day

Outpatient department of an NHS homeopathic hospital, UK

Y

External (charity; hom pharm—‘provided’ all remedies, presumably via hospital pharmacy dept)

U

A37

Walach

1997

Neurology

Headache

Patients diagnosed according to the International Headache Society classification criteria

Germany

Mixed

Homeoden (Gent) and Gudjons (Augsburg): supplied homeopathic medicines

U

A38

Weatherley-Jones

2004

Mental disorder

Chronic fatigue syndrome

Adults with chronic fatigue

Two outpatient departments in UK

U

External (charity)

Y

A39

White

2003

Allergy and asthma

Childhood asthma

Children, aged 5–15 years, with diagnosis of asthma and prescription for beta agonist and/or corticosteroid inhaler issued within previous 3 months

Five general practices in market towns in Somerset, UK

U

External, including hom pharm that provided all remedies

N

A40

Whitmarsh

1997

Neurology

Migraine

Adults aged 18–60 years, of either sex, with definite diagnosis of migraine by pre-defined criteria

Princess Margaret Migraine Clinic, Charing Cross Hospital, London, UK

Y

Nelsons Ltd; Homeopathic Medical Research Council; Blackie Foundation Trust

U

A41

Yakir

2001

Obstetrics and gynaecology

Premenstrual syndrome

Women aged 20–50 years, with diagnosis of PMS according to pre-defined criteria; symptomatology corresponding to one of five homeopathic medicines

Gynaecology outpatient clinic, Hadassah University Hospital, Jerusalem, Israel

Y

Dolisos Laboratories; Deutsche Homeopathie Union; named individuals

N

The complete bibliographic details for the studies included are found in Additional file 4. Y yes, U unclear, N no, RA rheumatoid arthritis, URTI upper respiratory tract infection. aVested interest: support (direct, through research sponsorship; indirect, via gifted medicines) from a company that provided homeopathic medicines for the trial.

Summary of findings

For each trial, Table 2 includes details of the sample size, the identified ‘main outcome measure’ (and whether dichotomous or continuous), the end-point and whether the study was described in the original report as a ‘pilot’ (or ‘preliminary’ or ‘feasibility’) study. The median sample size (for N = 32 trials) was 43.5 (inter-quartile range 27 to 67). There were 28 different ‘main outcome measures’ and for an end-point that ranged from 12 h to 12 months.
Table 2

Summary of findings table

#

First author

Year

Pilot

ITT sample

PP sample

PP sample > median(43.5)

Attrition rate(%)

‘Main’outcome identified

Nature of‘main’outcome

End-point

A01

Andrade

1991

N

44

33

N

25.0

Ritchie articular index

Continuous

6 months

A05

Bell

2004

Y

62

53

Y

14.5

Tender point pain on palpation

Continuous

3 months

A06

Bonne

2003

N

44

39

N

11.4

Hamilton Rating Scale for Anxiety (HAM-A)

Continuous

10 weeks

A07

Brien

2011

N

32

23

N

28.1

Proportion of patients meeting ACR 20% improvement criteria (‘ACR20 response’)

Dichotomous

28 weeks

A09

Cavalcanti

2003

N

28

20

N

28.6

Responders: patients with more than 50% reduction in pruritus score

Dichotomous

60 days

A10

Chapman

1999

Y

61

50

Y

18.0

SRH-SLPD functional assessment tool: SRS (symptoms) sub-scale

Continuous

4 months

A11

de Lange de Klerk

1994

N

175

170

Y

2.9

Daily total symptom score

Continuous

1 year

A13

Fisher

2006

Y

38

27

N

28.9

VAS of overall symptom severity

Continuous

13 weeks

A14

Frass

2005

N

70

67

Y

4.3

Patient survival

Dichotomous

180 days

A16

Gaucher

1994

N

80

51

Y

36.3

Degree of dehydration

Continuous

12 h

A18

Jacobs

1993

N

34

33

N

2.9

Number of days until fewer than 3 unformed stools for 2 consecutive days

Continuous

Up to 6 days

A19

Jacobs

1994

N

92

81

Y

12.0

Number of days until fewer than 3 unformed stools for 2 consecutive days

Continuous

Up to 5 days

A20

Jacobs

2001

Y

75

75

Y

0.0

Treatment failure

Dichotomous

5 days (cumulative total)

A21

Jacobs

2000

N

126

116

Y

7.9

Number of days until fewer than 3 unformed stools for 2 consecutive days

Continuous

5 days

A22

Jacobs

2005b

Y

53

33

N

37.7

Hot flash severity score

Continuous

12 months

A23

Jacobs

2005a

Y

43

37

N

14.0

Conners Global Index–Parent (CGI-P)—total

Continuous

17 weeks

A24

Jansen

1992

Y

10

4

N

60.0

Endoscopic appearance (grade)

Continuous

12 months

A25

Kainz

1996

N

67

60

Y

10.4

Responders: patients with at least 50% reduction in area of skin affected by warts

Dichotomous

8 weeks

A26

Katz

2005

Y

7

3

N

57.1

Hamilton Depression Scale (HAMD)

Continuous

12 weeks

A30

Naudé

2010

N

33

30

N

9.1

Sleep Impairment Index (SII) summary score

Continuous

4 weeks

A31

Rastogi ( a)

1999

N

50

42

N

16.0

CD4+ T-lymphocyte counts

Continuous

6 months

A31

Rastogi ( b)

1999

N

50

38

N

24.0

CD4+ T-lymphocyte counts

Continuous

6 months

A32

Sajedi

2008

N

24

16

N

33.3

Modified Ashworth Scale: measurement of muscle tone in right leg

Continuous

4 months

A33

Siebenwirth

2009

N

24

14

N

41.7

MP (multiparameter dermatitis) score

Continuous

32 weeks

A34

Steinsbekk

2005

N

251

199

Y

20.7

Parent-reported URTI total symptom score

Continuous

Duration of 12 weeks

A35

Straumsheim

2000

N

73

68

Y

6.8

Frequency of migraine attacks per month

Continuous

Last month of 4-month period

A36

Thompson

2005

Y

53

45

Y

15.1

MYMOP profile score

Continuous

16 weeks

A37

Walach

1997

N

98

92

Y

6.1

Frequency of headaches per month

Continuous

Last month of 3-month period

A38

Weatherley- Jones

2004

N

103

86

Y

16.5

Responders: those with clinical improvement (Multidimensional Fatigue Inventory: mental fatigue)

Dichotomous

7 months

A39

White

2003

N

89

74

Y

16.9

Childhood Asthma Questionnaire (CAQ) sub-scale for severity of symptoms

Continuous

52 weeks

A40

Whitmarsh

1997

N

63

60

Y

4.8

Frequency of migraine attacks per month

Continuous

Last month of 4-month period

A41

Yakir

2001

Y

23

19

N

17.4

Menstrual distress questionnaire (MDQ) score

Continuous

Duration of 3 months (last 7 days per cycle)

ITT intention to treat, PP per protocol, Y yes, N no.

Risk of bias and reliable evidence

Table 3 provides the risk-of-bias details for each of the 32 trials and sub-divided by (a) included in our meta-analysis and (b) not included in our meta-analysis. Domain IIIa (blinding of participants and trial personnel) contributed the least risk of bias overall, with no trial classed ‘high risk’. Domain IV (completeness of outcome data) presented the greatest methodological concerns, with 14 trials judged ‘high risk’. Domain II (allocation concealment) presented the most uncertain methodological judgments, with 21 (66%) trials assessed ‘unclear risk’ and 10 (31%) assessed ‘low risk’. A risk-of-bias bar graph is shown in Additional file 5.
Table 3

Risk-of-bias assessments for trials: (a) included in meta-analysis and (b) not included in meta-analysis

#

First author

Year

Risk-of-bias domain

Risk of bias

Risk-of-bias rating

I

II

IIIa

IIIb

IV

Va

VI

(a): Included in meta- analysis

A11

de Lange de Klerk

1994

U

U

U

U

Y

Y

Y

Uncertain

B4

A19

Jacobs

1994

Y

Y

Y

Y

U

Y

Y

Uncertainb

B1

A25

Kainz

1996

U

U

U

U

U

Y

U

Uncertain

B6

A10

Chapman

1999

Y

U

Y

Y

Y

Y

Y

Uncertain

B1

A35

Straumsheim

2000

U

U

Y

Y

Y

Y

Y

Uncertain

B2

A20

Jacobs

2001

Y

Y

Y

Y

U

Y

Y

Uncertainb

B1

A41

Yakir

2001

U

U

Y

Y

U

Y

Y

Uncertain

B3

A06

Bonne

2003

U

U

Y

Y

Y

Y

U

Uncertain

B3

A05

Bell

2004

Y

Y

Y

Y

Y

Y

U

Uncertainb

B1

A14

Frass

2005

Y

U

Y

U

Y

Y

Y

Uncertain

B2

A23

Jacobs

2005a

Y

U

Y

Y

Y

Y

Y

Uncertain

B1

A36

Thompson

2005

Y

U

Y

Y

Y

Y

Y

Uncertain

B1

A40

Whitmarsh

1997

U

U

Y

U

Y

U

N

High

C1.4

A31

Rastogi (a)

1999

U

U

U

U

N

N

U

High

C2.5

A31

Rastogi (b)

1999

U

U

U

U

N

N

U

High

C2.5

A09

Cavalcanti

2003

U

U

Y

Y

N

Y

U

High

C1.3

A38

Weatherley-Jones

2004

Y

U

Y

Y

N

Y

Y

High

C1.1

A22

Jacobs

2005b

Y

Y

Y

Y

N

Y

Y

High

C1.0

A13

Fisher

2006

Y

U

Y

Y

N

Y

U

High

C1.2

A32

Sajedi

2008

U

U

U

U

N

Y

Y

High

C1.4

A33

Siebenwirth

2009

U

Y

Y

Y

N

Y

N

High

C2.1

A07

Brien

2011

Y

Y

Y

Y

N

Y

Y

High

C1.0

(b): Not included in meta-analysis

A01

Andrade

1991

U

U

U

U

N

N

U

High

C2.5

A24

Jansen

1992

U

U

U

U

N

N

N

High

C3.4

A18

Jacobs

1993

U

U

Y

Y

U

N

U

High

C1.4

A16

Gaucher

1994

N

N

U

U

N

N

U

High

C4.3

A37

Walach

1997

U

Y

Y

U

Y

N

N

High

C2.2

A21

Jacobs

2000

Y

Y

Y

Y

Y

N

N

High

C2.0

A39

White

2003

Y

Y

Y

Y

Y

N

Y

High

C1.0

A26

Katz

2005

Y

U

Y

U

N

N

N

High

C3.2

A34

Steinsbekk

2005

Y

Y

Y

Y

N

N

Y

High

C2.0

A30

Naudé

2010

Y

U

Y

Y

U

N

Y

High

C1.2

Trials are arranged chronologically within their risk-of-bias rating category.

aUnless a published study protocol was available, completeness of reporting (domain V) was judged solely on correspondence of ‘Results’ with details in ‘Methods’ section of paper.

bReliable evidence.

Y yes, U unclear, N no (regarding freedom from risk of bias).

Table 3(a): No trial was ‘A’-rated (low risk of bias overall)—i.e. none fulfilled the criteria for all seven domains of assessment. Table 3(a) therefore includes a list of 12 trials that were classed uncertain risk of bias (‘B’-rated) and 10 that were classed high risk of bias (‘C’-rated). Table 3(a) also shows the three ‘B1’-rated trials that satisfied our criteria for reliable evidence. All other trials had unclear or high risk of bias in important methodological aspects and may be regarded as non-reliable evidence.

Table 3(b): Trials that were deficient in domain V (selective outcome reporting) included the ten whose data were not extractable for meta-analysis and which were thus ‘C’-rated by default; seven of these ten trials were already ‘C’-rated due to deficiency in at least one other domain of assessment.

Meta-analysis

The data extracted per trial (continuous or dichotomous data) are tabulated in Additional file 6. Figure 1 illustrates the OR for each trial; the original SMD data for each of the studies with continuous data are shown in Additional file 7. Of the 22 trials, 15 had an effect favouring homeopathy (i.e. OR > 1), 3 of them statistically significantly; 7 trials had an effect favouring placebo, none of them significantly. Total sample size = 1,123 (N = 22 trials).
https://static-content.springer.com/image/art%3A10.1186%2F2046-4053-3-142/MediaObjects/13643_2014_Article_328_Fig1_HTML.jpg
Figure 1

Forest plot showing odds ratio (OR) and 95% confidence interval (CI) for each of 22 RCTs of individualised homeopathy, with pooled OR (random-effects [RE] model) for trials with continuous outcomes, dichotomous outcomes, and for all 22 RCTs.

Pooled OR was 1.53 (95% confidence interval (CI) 1.22 to 1.91; P < 0.001). There was no difference depending on whether the ‘main outcome’ was continuous (OR = 1.45; 95% CI 1.12 to 1.89) or dichotomous (OR = 1.80 (95% CI 1.12 to 2.87); P = 0.44).

Heterogeneity and publication bias

Despite the clinical heterogeneity across the studies, the statistical heterogeneity between the studies was low (I 2 = 0% [95% CI 0% to 40%]), and therefore the variability in the estimated pooled OR is also relatively low. No evidence of publication bias was apparent from the funnel plot (Figure 2) or from Egger’s test (P = 0.59).
https://static-content.springer.com/image/art%3A10.1186%2F2046-4053-3-142/MediaObjects/13643_2014_Article_328_Fig2_HTML.jpg
Figure 2

Funnel plot: 22 RCTs of individualised homeopathy.

Risk of bias and reliable evidence

Figure 3a shows the OR data for all 22 trials, grouped by their ‘B’- or ‘C’-rating. There was no difference between ‘B’- and ‘C’-rated trials: P = 0.41.
https://static-content.springer.com/image/art%3A10.1186%2F2046-4053-3-142/MediaObjects/13643_2014_Article_328_Fig3_HTML.jpg
Figure 3

Forest plots showing odds ratio (OR) and 95%cconfidence interval (CI) for each of (a) 22 RCTs of individualised homeopathy, with pooled OR (random-effects [RE] model) for trials with unclear risk of bias (RoB), high RoB, and for all 22 RCTs; (b) 12 ‘B’-rated RCTs of individualised homeopathy, with pooled OR (RE model) for trials with non-reliable evidence, reliable evidence, and for all 12 RCTs.

  • ‘Uncertain risk of bias’ (all ‘B’-rated; N = 12): OR = 1.63 (95% CI 1.24 to 2.14; P < 0.001);

  • ‘High risk of bias’ (all ‘C’-rated; N = 10): OR = 1.33 (95% CI 0.90 to 1.98; P = 0.15).

  • Figure 3b shows the OR data for the 12 ‘B’-rated trials, grouped by reliability of evidence. There was no difference between the two sub-sets (P = 0.42).

  • Uncertain risk of bias/reliable evidence (N = 3): OR = 1.98 (95% CI 1.16 to 3.38; P = 0.013).

  • Uncertain risk of bias/non-reliable evidence (N = 9): OR = 1.53 (95% CI 1.09 to 2.14; P = 0.014).

Sensitivity analysis

Figure 4 shows the effect of removing data by trials’ risk-of-bias rating; full details are given in Additional file 8. The set of six trials rated ‘B1’ has been sub-divided by those with/without reliable evidence. The pooled OR showed a statistically significant effect in favour of homeopathy for every value of N, down to and including the final N = 3 trials with reliable evidence. Additional file 8 also states whether a trial was included in the ‘global’ analyses by Linde and/or Shang [6, 8]: of the 22 RCTs we subjected to meta-analysis, 8 had previously been analysed and 14 had not (our selected ‘main outcome measure’ differs for 3 of the 8 trials also included by Shang—Additional file 9).
https://static-content.springer.com/image/art%3A10.1186%2F2046-4053-3-142/MediaObjects/13643_2014_Article_328_Fig4_HTML.jpg
Figure 4

Sensitivity analysis, showing progressive effect on pooled odds ratio (OR) of removing data by trials’ risk-of-bias rating.

Sub-group analyses

Pooled OR favoured homeopathy for all sub-groups and was statistically significant for all but two of them (<median; potency not exclusively ≥12C): Figure 5a. There was no evidence of difference in the pooled statistic between any sub-groups. Similar results were seen for the N = 12 (Figure 5b) and N = 3 analyses (data not illustrated). Full details are given in Additional file 10. We observed a statistically significant pooled OR, favouring homeopathy, for the eight trials that we have in common with those previously reported by Shang et al. [8].
https://static-content.springer.com/image/art%3A10.1186%2F2046-4053-3-142/MediaObjects/13643_2014_Article_328_Fig5_HTML.jpg
Figure 5

Interactions between sub-groups for (a) all N  = 22 trials with analysable data and (b) N  = 12 ‘B’- rated trials.

Discussion

Twenty-nine of the 32 trials had unclear or high risk of bias in important domains of assessment. Poor reporting or other deficiencies in the original papers prevented data extraction for meta-analysis from 10 of the 32 trials; the potential influence of the 10 on our overall meta-analysis is unknown, but because of their intrinsic low quality, their absence does not alter our principal conclusions. High and unclear risk of bias featured almost equally in our 22-trial analysis; thus, the overall quality of analysed evidence was low or unclear, necessitating caution in interpreting the findings.

As was the case for the previous ‘global’ systematic reviews of homeopathy RCTs that have included meta-analysis [6, 8], there are obvious limitations in pooling data from diverse medical conditions, outcome measures and end-points. Thus, a given pooled effects estimate here does not have a clear numerical meaning or relative clinical value: it is a summary measure that enables statistical significance and mean ‘effect size’ to be attributed and to be interpreted in testing an hypothesis that individually prescribed homeopathic medicines have specific effects.

Though our conclusions can be made most securely from three trials with reliable evidence, this sub-set of studies is too small to enable a decisive answer to our tested hypothesis. Equivocal RCT evidence of this nature is not unusual in medical science, in which conclusions are commonly based on just two eligible RCTs per systematic review [17]. Given the specific focus of our study, a statistically significant OR of 1.98 may be interpreted as a small ‘effect size’ for these three trials collectively and does not differ significantly from the ‘effect size’ observed in our analysis of 22 trials (OR = 1.53). Such ‘effect sizes’ seem comparable with, for example, sumatriptan for migraine, fluoxetine for major depressive disorder and cholinesterase inhibitors for dementia [18]. The detection of a small yet significant pooled OR, with the perspective that only a few single trials showed statistically significant effects, supports conjecture that the impact of an individualised homeopathic prescription may be difficult to observe readily in the context of any one particular placebo-controlled trial [19, 20].

Our approach to quality assessment was objective and internally consistent, and the methodological implications of our risk-of-bias findings are the same as those for RCTs in conventional medicine. Indeed, it is noteworthy that domain II (allocation concealment) had the fewest ‘low risk of bias’ assessments (for 31% of our trials): this compares historically with adequately described allocation concealment in just 16% conventional medicine trials that were published during the period 1960 to 1995 [21].

Two of the three trials with reliable evidence used medicines that were diluted beyond the Avogadro limit. Our pooled effects estimate for the three trials, therefore, is either a false positive or it reflects the relevance of new hypotheses about the biological mechanism of action of homeopathic dilutions [22, 23]. It should also be noted that one of these same three trials displayed evidence of vested interest. It remains to be seen if our assessments of model validity [24] support or refute the legitimacy of these three trials as currently the most important contributors to the evidence base in individualised homeopathy.

Comparison with previous systematic reviews

Our database is different from that of both Linde and Shang [6, 8]. Firstly, we concentrated solely on peer-reviewed trials of individualised homeopathic treatment. Secondly, we have an updated set of trials for meta-analysis: 14 of our 22 RCTs were not included in the previous ‘global’ analyses. Thirdly, our selected ‘main outcome measure’—and thus our calculated OR—differs for three of the eight previously analysed trials of individualised homeopathy. Fourthly, our group of three RCTs with ‘reliable evidence’ is founded on a more exacting standard than for Shang’s ‘trials of higher methodological quality’: indeed, by Shang’s explicit criteria for domains IV, V and VI, we would label five of our ‘non-reliable’ trials [20, 2528] as ‘higher methodological quality’.

A notable finding from sub-group analysis is that our 14 newly examined trials do not differ in ‘effect size’ from the eight that were included in previous ‘global’ meta-analysis by Shang et al. [8], disputing suggestions that the evidence base in homeopathy is weakening with time [29]. Noteworthy too is the significantly positive pooled OR that we observed for those eight trials and the close similarity of its value to that calculable from Shang’s forest plot data for the same eight [30].

Like us, Linde and colleagues reported a pooled OR of 1.50–2.00 for the highest-quality RCTs [3, 6]. In their separate analysis of individualised homeopathy, however, Linde and Melchart noted a smaller ‘effect size’ whose statistical significance was only marginally not sustained for the highest-quality trials [9]. Unlike our predecessors, we found no evidence that lower-quality trials displayed a larger treatment effect than that of higher-quality studies: indeed, our ten ‘C’-rated trials with extractable data displayed a non-significant pooled effects estimate. It may be that our stringent judgmental approach led to a less extreme range of quality assessments than those of the earlier reviewers. Importantly, we found no evidence of publication bias, removing any need for data adjustment.

Conclusions

  • There was a small, statistically significant, treatment effect of individualised homeopathic treatment that was robust to sensitivity analysis based on ‘reliable evidence’.

  • Findings are consistent with sub-group data available in a previous ‘global’ systematic review of homeopathy RCTs.

  • The overall quality of the evidence was low or unclear, preventing decisive conclusions.

  • New RCT research of high quality on individualised homeopathy is required to enhance the totality of reliable evidence and thus enable clearer interpretation and a more informed scientific debate.

Authors’ information

The study is intrinsic to the work of the British Homeopathic Association through its Research Development Adviser, RTM; it was assisted by a grant from the Manchester Homeopathic Clinic (see below). Trustees and staff of neither charity contributed to the design, analysis or write-up. RTM devised and led the study in collaboration with his co-authors.

Abbreviations

CI: 

Confidence interval

OR: 

Odds ratio

RCT: 

Randomised controlled trial

SMD: 

Standardised mean difference

WHO: 

World Health Organization.

Declarations

Acknowledgements

The study was supported by a grant from the Manchester Homeopathic Clinic to the British Homeopathic Association.

Authors’ Affiliations

(1)
British Homeopathic Association
(2)
Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow
(3)
Department of Biomedical Engineering, University of Strathclyde
(4)
Karl und Veronica Carstens-Stiftung
(5)
Homeopathy Research Institute
(6)
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center

References

  1. Vithoulkas G: Another point of view for the homeopathic trials and meta-analyses. [http://www.vithoulkas.com/en/research/articles/2247.html]
  2. Sense About Science: Homeopathy. [http://www.senseaboutscience.org/data/files/resources/54/Homeopathy.pdf.]
  3. Linde K, Scholz M, Ramirez G, Clausius N, Melchart D, Jonas WB: Impact of study quality on outcome in placebo-controlled trials of homeopathy. J Clin Epidemiol. 1999, 52: 631-636. 10.1016/S0895-4356(99)00048-7.View ArticlePubMedGoogle Scholar
  4. Kleijnen J, Knipschild P, ter Riet G: Clinical trials of homoeopathy. BMJ. 1991, 302: 316-323. 10.1136/bmj.302.6772.316.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Boissel JP, Cucherat M, Haugh M, Gauthier E: Critical literature review on the effectiveness of homoeopathy: overview of data from homoeopathic medicine trials. Homoeopathic Medicine Research Group, Report of the Commission of the European Communities, Directorate-General XII – Science, Research and Development, Directorate E – RTD Actions. 1996, Brussels, Belgium: Life Sciences and Technologies – Medical ResearchGoogle Scholar
  6. Linde K, Clausius N, Ramirez G, Melchart D, Eitel F, Hedges LV, Jonas WB: Are the clinical effects of homoeopathy placebo effects? A meta-analysis of placebo-controlled trials. Lancet. 1997, 350: 834-843. 10.1016/S0140-6736(97)02293-9.View ArticlePubMedGoogle Scholar
  7. Cucherat M, Haugh MC, Gooch M, Boissel JP: Evidence of clinical efficacy of homeopathy. A meta-analysis of clinical trials. Eur J Clin Pharmacol. 2000, 56: 27-33. 10.1007/s002280050716.View ArticlePubMedGoogle Scholar
  8. Shang A, Huwiler-Muntener K, Nartey L, Juntherapiesi P, Dorig S, Sterne JA, Pewsner D, Egger M: Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy. Lancet. 2005, 366: 726-732. 10.1016/S0140-6736(05)67177-2.View ArticlePubMedGoogle Scholar
  9. Linde K, Melchart D: Randomized controlled trials of individualized homeopathy: a state-of-the-art review. J Altern Complement Med. 1998, 4: 371-388.View ArticlePubMedGoogle Scholar
  10. Mathie RT, Legg LA, Clausen J, Davidson JRT, Lloyd SM, Ford I: Systematic review and meta-analysis of randomised, placebo-controlled, trials of individualised homeopathic treatment: study protocol. Version 1.0; 25 January 2013. [http://www.britishhomeopathic.org/wp-content/uploads/2013/05/Study_protocol_for_systematic_review.pdf]
  11. Mathie RT, Hacke D, Clausen J, Nicolai T, Riley DS, Fisher P: Randomised controlled trials of homeopathy in humans: characterising the research journal literature for systematic review. Homeopathy. 2013, 102: 3-24. 10.1016/j.homp.2012.10.002.View ArticlePubMedGoogle Scholar
  12. World Health Organization: Towards a Common Language for Functioning, Disability and Health: The International Classification of Functioning, Disability and Health (ICF). 2002, Geneva: World Health OrganizationGoogle Scholar
  13. Higgins JPT, Altman DG: Chapter 8: Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. Edited by: Higgins JPT, Green S. 2011, The Cochrane CollaborationGoogle Scholar
  14. Sterne JAC, Egger M, Moher D: Chapter 10: Addressing reporting biases. Cochrane Handbook for Systematic Reviews of Interventions; Version 5.1.0. Edited by: Higgins JPT, Green S. 2011, The Cochrane CollaborationGoogle Scholar
  15. Egger M, Smith GD, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997, 315: 629-634. 10.1136/bmj.315.7109.629.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Bellavite P, Marzotto M, Olioso D, Moratti E, Conforti A: High-dilution effects revisited. 1. Physicochemical aspects. Homeopathy. 2014, 103: 4-21. 10.1016/j.homp.2013.08.003.View ArticlePubMedGoogle Scholar
  17. El Dib RP, Atallah AN, Andriolo RB: Mapping the Cochrane evidence for decision making in health care. J Eval Clin Pract. 2007, 13: 689-692. 10.1111/j.1365-2753.2007.00886.x.View ArticlePubMedGoogle Scholar
  18. Leucht S, Hierl S, Kissling W, Dold M, Davis JM: Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry. 2012, 200: 97-106. 10.1192/bjp.bp.111.096594.View ArticlePubMedGoogle Scholar
  19. Weatherley-Jones E, Thompson EA, Thomas KJ: The placebo-controlled trial as a test of complementary and alternative medicine: observations from research experience of individualised homeopathic treatment. Homeopathy. 2004, 93: 186-189. 10.1016/j.homp.2004.06.002.View ArticlePubMedGoogle Scholar
  20. Brien S, Lachance L, Prescott P, McDermott C, Lewith G: Homeopathy has clinical benefits in rheumatoid arthritis patients that are attributable to the consultation process but not the homeopathic remedy: a randomized controlled clinical trial. Rheumatology (Oxford). 2011, 50: 1070-1082. 10.1093/rheumatology/keq234.View ArticleGoogle Scholar
  21. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP: Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet. 1998, 352: 609-613. 10.1016/S0140-6736(98)01085-X.View ArticlePubMedGoogle Scholar
  22. Bell IR, Koithan M: A model for homeopathic remedy effects: low dose nanoparticles, allostatic cross-adaptation, and time-dependent sensitization in a complex adaptive system. BMC Complement Altern Med. 2012, 12: 191-10.1186/1472-6882-12-191.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Bellavite P, Marzotto M, Olioso D, Moratti E, Conforti A: High-dilution effects revisited. 2. Pharmacodynamic mechanisms. Homeopathy. 2014, 103: 22-43. 10.1016/j.homp.2013.08.002.View ArticlePubMedGoogle Scholar
  24. Mathie RT, Roniger H, Van Wassenhoven M, Frye J, Jacobs J, Oberbaum M, Bordet M-F, Nayak C, Chaufferin G, Ives JA, Dantas F, Fisher P: Method for appraising model validity of randomised controlled trials of homeopathic treatment: multi-rater concordance study. BMC Med Res Methodol. 2012, 12: 49-10.1186/1471-2288-12-49.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Jacobs J, Herman P, Heron K, Olsen S, Vaughters L: Homeopathy for menopausal symptoms in breast cancer survivors: a preliminary randomized controlled trial. J Altern Complement Med. 2005, 11: 21-27. 10.1089/acm.2005.11.21.View ArticlePubMedGoogle Scholar
  26. Jacobs J, Jimenez LM, Malthouse S, Chapman E, Crothers D, Masuk M, Jonas WB: Homeopathic treatment of acute childhood diarrhoea: results from a clinical trial in Nepal. J Altern Complement Med. 2000, 6: 131-139. 10.1089/acm.2000.6.131.View ArticlePubMedGoogle Scholar
  27. White A, Slade P, Hunt C, Hart A, Ernst E: Individualised homeopathy as an adjunct in the treatment of childhood asthma: a randomised placebo controlled trial. Thorax. 2003, 58: 317-321. 10.1136/thorax.58.4.317.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Steinsbekk A, Bentzen N, Fønnebø V, Lewith G: Self treatment with one of three self selected, ultramolecular homeopathic medicines for the prevention of upper respiratory tract infections in children. A double-blind randomized placebo controlled trial. Br J Clin Pharmacol. 2005, 59: 447-455. 10.1111/j.1365-2125.2005.02336.x.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Ernst E, Pittler MH, Wider B, Boddy K: Homeopathy: is the evidence-base changing?. Perfusion. 2006, 19: 380-382.Google Scholar
  30. British Homeopathic Association: Data from randomised controlled trials of individualised homeopathy, reported by Shang et al. in 2005. [http://www.britishhomeopathic.org/wp-content/uploads/2014/11/Shang-re-analysis-individualised.pdf]

Copyright

© Mathie et al.; licensee BioMed Central. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement